Researchers at Zhejiang University, China, have explored mechanisms for the sustained antidepressant effects of ketamine, suggesting that a direct N-methyl-D-aspartate receptor (NMDAR) blockade might ...

NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Researchers at Bexson Biomedical Inc. and Saint Joseph’s University have synthesized NMDA receptor antagonists reported to be useful for the treatment of neurological and psychiatric disorders.

Despite growing off-label use, ketamine and related NMDA blockers show no reliable evidence of easing chronic pain, highlighting the urgent need for safer and more effective treatments. Review: ...

A new study reveals a critical vulnerability in a brain receptor targeted by a rare autoimmune disease. Researchers have moved a step closer to new treatments for a rare and often devastating ...

Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial. The drugs are all ...